Information Provided By: 
Fly News Breaks for February 22, 2018
ARQL
Feb 22, 2018 | 07:26 EDT
Roth Capital analyst Jotin Marango started ArQule with a Buy rating and $5 price target, contending that near and medium term value inflections for its AKT and BTK inhibitors could be "transformational for the company and its investors." He advises investors to keep an eye on initial data from the first cohort of the Phase 1 study of ARQ 531 in refractory B-cell tumors, likely at AACR in April and/or ASCO in June, as well as the publication of full data from the NIH Phase 1 study of Miransertib in Proteus.
News For ARQL From the Last 2 Days
There are no results for your query ARQL
